MD1663C2 - Compoziţie şi metode pentru modularea reacţiei sexuale umane şi tratamentul impotenţei - Google Patents

Compoziţie şi metode pentru modularea reacţiei sexuale umane şi tratamentul impotenţei Download PDF

Info

Publication number
MD1663C2
MD1663C2 MD98-0007A MD980007A MD1663C2 MD 1663 C2 MD1663 C2 MD 1663C2 MD 980007 A MD980007 A MD 980007A MD 1663 C2 MD1663 C2 MD 1663C2
Authority
MD
Moldova
Prior art keywords
impotency
composition
treatment
methods
sexual activity
Prior art date
Application number
MD98-0007A
Other languages
English (en)
Russian (ru)
Other versions
MD980007A (ro
MD1663B2 (ro
Inventor
Fred Lowrey
Original Assignee
Zonagen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zonagen, Inc. filed Critical Zonagen, Inc.
Publication of MD980007A publication Critical patent/MD980007A/ro
Publication of MD1663B2 publication Critical patent/MD1663B2/ro
Publication of MD1663C2 publication Critical patent/MD1663C2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Invenţia se referă la medicină.Esenţa invenţiei constă în aceea că per os se administrează compoziţie, conţinând un vasodilatator, în formă de tablete, prafuri şi pastile cu o perioadă de dezintegrare de până la 20 min.
MD98-0007A 1995-04-28 1996-04-26 Compoziţie şi metode pentru modularea reacţiei sexuale umane şi tratamentul impotenţei MD1663C2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/431,145 US5731339A (en) 1995-04-28 1995-04-28 Methods and formulations for modulating the human sexual response
PCT/US1996/005816 WO1996033705A1 (en) 1995-04-28 1996-04-26 Methods and formulations for modulating the human sexual response

Publications (3)

Publication Number Publication Date
MD980007A MD980007A (ro) 1999-07-31
MD1663B2 MD1663B2 (ro) 2001-05-31
MD1663C2 true MD1663C2 (ro) 2001-11-30

Family

ID=23710676

Family Applications (1)

Application Number Title Priority Date Filing Date
MD98-0007A MD1663C2 (ro) 1995-04-28 1996-04-26 Compoziţie şi metode pentru modularea reacţiei sexuale umane şi tratamentul impotenţei

Country Status (35)

Country Link
US (6) US5731339A (ro)
EP (2) EP0767660B1 (ro)
JP (2) JP3469901B2 (ro)
KR (1) KR100363056B1 (ro)
CN (1) CN101816638A (ro)
AR (1) AR001739A1 (ro)
AT (1) ATE185695T1 (ro)
AU (1) AU710111B2 (ro)
BG (1) BG63071B1 (ro)
BR (1) BR9604983A (ro)
CA (1) CA2219502C (ro)
CZ (1) CZ294350B6 (ro)
DE (1) DE69604762T2 (ro)
DK (1) DK0767660T3 (ro)
EE (1) EE03472B1 (ro)
ES (1) ES2140847T3 (ro)
GR (1) GR3032182T3 (ro)
HU (1) HU222044B1 (ro)
IL (1) IL117871A (ro)
IS (1) IS4598A (ro)
LT (1) LT4404B (ro)
LV (1) LV12038B (ro)
MD (1) MD1663C2 (ro)
NO (1) NO314746B1 (ro)
NZ (1) NZ307020A (ro)
PL (1) PL185528B1 (ro)
PT (1) PT767660E (ro)
RO (1) RO116866B1 (ro)
RU (2) RU2239424C2 (ro)
SI (1) SI9620058A (ro)
SK (1) SK283847B6 (ro)
TR (2) TR199701260T1 (ro)
UA (1) UA70277C2 (ro)
WO (1) WO1996033705A1 (ro)
ZA (1) ZA963380B (ro)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US6387407B1 (en) 1995-09-29 2002-05-14 L.A.M. Pharmaceutical Corporation Topical drug preparations
US6251436B1 (en) 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US5897880A (en) 1995-09-29 1999-04-27 Lam Pharmaceuticals, Llc. Topical drug preparations
US6036977A (en) * 1995-09-29 2000-03-14 L.A.M. Pharmaceutical Corp. Drug preparations for treating sexual dysfunction
US6258032B1 (en) * 1997-01-29 2001-07-10 William M. Hammesfahr Method of diagnosis and treatment and related compositions and apparatus
US6469065B1 (en) 1996-02-02 2002-10-22 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US6323211B1 (en) 1996-02-02 2001-11-27 Nitromed, Inc. Compositions and methods for treating sexual dysfunctions
US6294517B1 (en) 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US20020143007A1 (en) * 1996-02-02 2002-10-03 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
USRE37234E1 (en) 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
GR1002847B (el) 1997-05-06 1998-01-27 Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
KR20010012721A (ko) * 1997-05-19 2001-02-26 조나젠 인코포레이티드 인간의 성적 반응을 조정하기 위한 복합 요법
US20030004170A1 (en) * 1997-05-19 2003-01-02 Zonagen, Inc. Combination therapy for modulating the human sexual response
AU756136B2 (en) 1997-06-23 2003-01-02 Queen's University At Kingston Microdose therapy
US6399618B1 (en) 1997-07-09 2002-06-04 Cardiome Pharma Corp Compositions and methods for modulating sexual activity
US6103765A (en) 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
KR20010021625A (ko) 1997-07-09 2001-03-15 추후보정 개선된 남성발기 기능장애 치료방법 및 그 조성물
US5947901A (en) 1997-09-09 1999-09-07 Redano; Richard T. Method for hemodynamic stimulation and monitoring
US6593369B2 (en) 1997-10-20 2003-07-15 Vivus, Inc. Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US20050070516A1 (en) * 1997-10-28 2005-03-31 Vivus Inc. As-needed administration of an androgenic agent to enhance female desire and responsiveness
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
AU740758B2 (en) * 1997-10-28 2001-11-15 Vivus, Inc. Treatment of female sexual dysfunction
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
US6169914B1 (en) 1998-01-13 2001-01-02 Urometrics, Inc. Devices and methods for monitoring female arousal
FR2774593B1 (fr) * 1998-02-12 2000-05-05 Philippe Gorny Obtention d'un medicament destine a combattre les dysfonctions sexuelles feminines
WO1999059584A1 (en) * 1998-05-20 1999-11-25 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
US6011043A (en) * 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6031005A (en) * 1998-08-03 2000-02-29 Easterling; W. Jerry Composition and method for treating Peyronie's disease and related connective tissue disorders
US6627663B2 (en) 1998-08-03 2003-09-30 W. Jerry Easterling Noninvasive method for treating hemangiomas through transdermal delivery of calcium channel blocker agents and medicament for use in such method
US20040170675A1 (en) * 1998-08-03 2004-09-02 Easterling W. Jerry Noninvasive method for treating cellulite through transdermal delivery of calcium channel blocker agents and medicament for use in such method
US6525100B1 (en) 1998-08-03 2003-02-25 W. Jerry Easterling Composition and method for treating peyronie's disease and related fibrotic tissue disorders
GR1003199B (el) * 1998-08-14 1999-09-01 Χρηση της μισοπροστολης ή και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση της σεξουαλικης δυσλειτουργιας στις γυναικες
EP1235563A2 (en) * 1998-08-26 2002-09-04 Queen's University At Kingston Use of anti(w)pressor agents for vascular remodeling in genital dysfunction
US6482426B1 (en) * 1998-09-17 2002-11-19 Zonagen, Inc. Compositions for the treatment of male erectile dysfunction
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6706682B2 (en) * 1999-01-21 2004-03-16 The Trustees Of Columbia University In The City Of New York Uses of vascular endothelial growth factor in the treatment of erectile dysfunction
CA2362918A1 (en) * 1999-03-08 2000-09-14 Elizabeth Stoner Methods and compositions for treating erectile dysfunction
CN1374861A (zh) * 1999-04-06 2002-10-16 佐纳根有限公司 调节人的性反应的方法
US6613768B1 (en) 1999-04-30 2003-09-02 Lilly Icos Llc Treatment of female arousal disorder
IT1312310B1 (it) 1999-05-07 2002-04-15 Recordati Ind Chimica E Farma Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale
US20010003120A1 (en) * 1999-05-14 2001-06-07 M. D. Robert Hines Method for treating erectile dysfunction
US6916845B2 (en) * 1999-06-17 2005-07-12 Zhongcheng Xin Method for prevention and treatment of male and female sexual dysfunction
US6730065B1 (en) * 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US6399591B1 (en) * 2000-01-19 2002-06-04 Yung-Shin Pharmaceutical Ind. Co., Ltd. Chargeable pharmaceutical tablets
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
AU2001259848B2 (en) * 2000-05-12 2005-10-13 Septodont Holding Sas Local anesthetic methods and kits
CA2417552C (en) 2000-06-27 2014-05-13 Qualilife Pharmaceuticals Inc. Compositions and methods for treating females sexual response
BRPI0003386B8 (pt) * 2000-08-08 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
KR20020020536A (ko) * 2000-09-09 2002-03-15 장우영 발기유발제
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US20060211753A1 (en) * 2000-11-03 2006-09-21 Ocularis Pharma, Inc. Method and composition which reduces stimulation of muscles which dilate the eye
US20020107230A1 (en) * 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
WO2002069906A2 (en) 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
US20020172712A1 (en) * 2001-03-19 2002-11-21 Alan Drizen Antiemetic, anti-motion sustained release drug delivery system
US20030138494A1 (en) * 2001-05-15 2003-07-24 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
CA2457433A1 (en) 2001-08-10 2003-02-20 Molecular Design International Inc. Novel alpha adrenergic agents
CN1315835C (zh) * 2001-08-28 2007-05-16 先灵公司 多环鸟嘌呤磷酸二酯酶v抑制剂
GB0130704D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd New use
AU2003286555A1 (en) * 2002-10-22 2004-05-13 Harbor-Ucla Research And Education Institute Phosphodiester inhibitors and nitric oxide modulators for treating peyronie's disease, arteriosclerosis and other fibrotic diseases
US8133903B2 (en) * 2003-10-21 2012-03-13 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
RU2228754C1 (ru) * 2003-06-19 2004-05-20 Сегал Александр Самуилович Способ лечения и профилактики эректильной дисфункции
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
CN100336506C (zh) * 2004-04-23 2007-09-12 北京科信必成医药科技发展有限公司 甲磺酸酚妥拉明口腔崩解片及其制备方法
RS52945B (sr) 2004-05-11 2014-02-28 Emotional Brain B.V. Farmaceutske formulacije i njihova primena u lečenju ženske seksualne disfunkcije
EP1750862B1 (en) * 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US20060252734A1 (en) * 2004-09-08 2006-11-09 Woodward John R Methods of female sexual enhancement
US20060167022A1 (en) * 2004-09-08 2006-07-27 Woodward John R Method of female sexual enhancement
US20080119445A1 (en) * 2004-09-08 2008-05-22 Woodward John R Methods of female sexual enhancement
US20060276442A1 (en) * 2004-09-08 2006-12-07 Woodward John R Methods of female sexual enhancement
US20060052402A1 (en) * 2004-09-08 2006-03-09 Woodward John R Method of female sexual enhancement
EP1802277B1 (de) * 2004-10-18 2010-01-13 Polymun Scientific Immunbiologische Forschung GmbH Liposomale zusammensetzung einen wirkstoff zur relaxierung glatter muskulatur enthaltend, die herstellung dieser zusammensetzung und deren therapeutische verwendung
WO2006084082A1 (en) * 2005-02-03 2006-08-10 Duramed Pharmaceuticals, Inc. Compositions of unconjugated estrogens and methods for their use
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
CA2624788C (en) 2005-10-12 2011-04-19 Unimed Pharmaceuticals, Llc Improved testosterone gel and method of use
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
EP2157937B1 (en) 2007-06-04 2017-03-22 Sequent Medical, Inc. Devices for treatment of vascular defects
EP3421043B1 (en) * 2012-12-05 2021-04-07 GE Nutrients, Inc. Use of fenugreek extract to enhance female libido
EP2950800B1 (en) 2013-02-01 2020-09-09 Ocuphire Pharma, Inc. Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
CA2899339C (en) 2013-02-01 2021-07-06 Ocularis Pharma, Llc Aqueous ophthalmic solutions of phentolamine and medical uses thereof
CN104013588A (zh) * 2014-04-14 2014-09-03 杨荣辰 一种甲磺酸酚妥拉明分散片及其制备方法
WO2016167254A1 (ja) * 2015-04-17 2016-10-20 株式会社山田養蜂場本社 蜂の子を含有する滋養強壮剤
WO2017100324A1 (en) * 2015-12-10 2017-06-15 Repros Therapeutics Inc. Combination therapy for treating female hypoactive sexual desire disorders
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN113164451A (zh) 2018-10-15 2021-07-23 奥库菲尔制药股份有限公司 治疗青光眼的方法和组合物及相关病症
EP3870170A4 (en) 2018-10-26 2022-07-20 Ocuphire Pharma, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF PRESBYOPIA, MYDRIASIS AND OTHER EYE DISEASES
CN115368310B (zh) 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3943246A (en) * 1972-07-10 1976-03-09 Sandoz Ltd. Organic compounds
US4127118A (en) * 1977-03-16 1978-11-28 Alvaro Latorre Method of effecting and enhancing an erection
US4139617A (en) * 1974-05-13 1979-02-13 Richardson-Merrell Inc. 19-Oxygenated-androst-5-enes for the enhancement of libido
US4530920A (en) * 1983-11-07 1985-07-23 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US4863911A (en) * 1986-08-04 1989-09-05 University Of Florida Method for treating male sexual dysfunction
US4885173A (en) * 1985-05-01 1989-12-05 University Of Utah Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities
US5059603A (en) * 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
US5065744A (en) * 1989-06-16 1991-11-19 Zusmanovsky Zinovy A Device for treatment of sexual impotence in human males
US5079018A (en) * 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
WO1995005172A1 (en) * 1993-08-13 1995-02-23 Zonagen, Inc. Methods for modulating the human sexual response
CA2219502A1 (en) * 1995-04-28 1996-10-31 Zonagen, Inc. Methods and formulations for modulating the human sexual response

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2503059A (en) * 1950-04-04 Nxchj
US3937834A (en) * 1970-10-02 1976-02-10 Ciba-Geigy Corporation Pharmaceutical preparations
NZ179623A (en) * 1975-01-06 1978-03-06 Ciba Geigy Pharmaceutical preparation containing a beta-receptor blocking compound, a compound regulating thrombocyte function and optionally an alpha-receptor blocking compund
GB1500300A (en) * 1975-01-06 1978-02-08 Ciba Geigy Ag Pharmaceutical preparation for the treatment of circulatory disorders
DE2965278D1 (en) * 1978-07-21 1983-06-01 Ciba Geigy Ag Pharmaceutical mixtures containing an amantadine compound
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
EP0152379A3 (de) * 1984-02-15 1986-10-29 Ciba-Geigy Ag Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
SE463851B (sv) * 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
FR2649613B1 (fr) * 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
US5236904A (en) * 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US5399581A (en) * 1990-12-26 1995-03-21 Laragh; John H. Method and compositions for treatment of sexual impotence
US5298261A (en) * 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3943246A (en) * 1972-07-10 1976-03-09 Sandoz Ltd. Organic compounds
US4139617A (en) * 1974-05-13 1979-02-13 Richardson-Merrell Inc. 19-Oxygenated-androst-5-enes for the enhancement of libido
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4127118A (en) * 1977-03-16 1978-11-28 Alvaro Latorre Method of effecting and enhancing an erection
US4530920A (en) * 1983-11-07 1985-07-23 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
US4885173A (en) * 1985-05-01 1989-12-05 University Of Utah Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities
US4863911A (en) * 1986-08-04 1989-09-05 University Of Florida Method for treating male sexual dysfunction
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5059603A (en) * 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
US5065744A (en) * 1989-06-16 1991-11-19 Zusmanovsky Zinovy A Device for treatment of sexual impotence in human males
US5079018A (en) * 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
WO1995005172A1 (en) * 1993-08-13 1995-02-23 Zonagen, Inc. Methods for modulating the human sexual response
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
CA2219502A1 (en) * 1995-04-28 1996-10-31 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US5981563A (en) * 1995-04-28 1999-11-09 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US6051594A (en) * 1995-04-28 2000-04-18 Zonagen, Inc. Methods and formulations for modulating the human sexual response

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Althof, S. E. et al. Sexual, psychological, and marital impact of self-injection of papaverine and phentolamine; a long-term prospective study. J. Sex & Marital Ther., vol.17(2), 1991, p. 101-112 *
Brindley, G. S. Pilot experiments on the actions of drugs injected into the human corpus cavernosum penis. Br. J. Pharmac., vol. 87, 1986, p. 495-500 *
Brindley, G. S., Cavernosal Alpha-Blockade. A New Technique for Investigating and treating Erectile Impotence. Brit. J. Psychiat., vol.143, 1983, p. 332-337 *
Corriere, Jr. et al. Development of Fibrotic Penile Lesions Secondary to the Intracorporeal Injection of Vasoactive Agents. J. Urol., vol. 140, 1988, p. 615-617 *
Gwinup, G. Oral Phentolamine in Nonspecific Erectile Insufficiency. Ann. Int. Med., 15 Jul. 1988, p.162-163 *
Sonda, L. P. et al. The Role of Yohimbine for the Treatment of Erectile Impotence. J. Sex & Marital Ther., vol. 16(1), 1990, p.15-21 *
Zorgniotti, A. W. et al. Auto-Injection of the Corpus Cavernosum with a Vasoactive Drug Combination for Vasculogenic Impotence. J. Urol., vol.133, 1985, p. 39-41 *

Also Published As

Publication number Publication date
EP0962225A3 (en) 2000-05-10
AR001739A1 (es) 1997-11-26
PL185528B1 (pl) 2003-05-30
BG102010A (en) 1998-04-30
EP0767660A1 (en) 1997-04-16
EP0962225A2 (en) 1999-12-08
BR9604983A (pt) 1999-06-15
LV12038B (en) 1998-08-20
HUP9802825A3 (en) 2000-06-28
CZ294350B6 (cs) 2004-12-15
BG63071B1 (bg) 2001-03-30
AU710111B2 (en) 1999-09-16
ES2140847T3 (es) 2000-03-01
SI9620058A (sl) 1998-06-30
NO974965D0 (no) 1997-10-27
SK283847B6 (sk) 2004-03-02
US6051594A (en) 2000-04-18
US6100286A (en) 2000-08-08
IS4598A (is) 1997-10-24
NO974965L (no) 1997-12-23
CN101816638A (zh) 2010-09-01
JPH11504902A (ja) 1999-05-11
PT767660E (pt) 2000-04-28
LT97168A (en) 1998-06-25
CA2219502A1 (en) 1996-10-31
RO116866B1 (ro) 2001-07-30
US5731339A (en) 1998-03-24
WO1996033705A1 (en) 1996-10-31
CA2219502C (en) 2002-11-19
DE69604762T2 (de) 2000-03-09
DE69604762D1 (de) 1999-11-25
GR3032182T3 (en) 2000-04-27
RU2177786C2 (ru) 2002-01-10
KR100363056B1 (ko) 2003-04-10
EP0767660A4 (en) 1997-08-27
EE03472B1 (et) 2001-08-15
JP2002087957A (ja) 2002-03-27
ZA963380B (en) 1996-11-08
LT4404B (lt) 1998-11-25
NO314746B1 (no) 2003-05-19
NZ307020A (ro) 1999-06-29
CZ339397A3 (cs) 1998-03-18
SK145897A3 (en) 1998-06-03
IL117871A0 (en) 1996-08-04
MD980007A (ro) 1999-07-31
US6166061A (en) 2000-12-26
UA70277C2 (en) 2004-10-15
JP3469901B2 (ja) 2003-11-25
ATE185695T1 (de) 1999-11-15
EP0767660B1 (en) 1999-10-20
IL117871A (en) 2001-01-11
MD1663B2 (ro) 2001-05-31
DK0767660T3 (da) 2000-04-25
JP4531301B2 (ja) 2010-08-25
EE9700276A (et) 1998-04-15
LV12038A (lv) 1998-05-20
HU222044B1 (hu) 2003-04-28
AU5576896A (en) 1996-11-18
RU2239424C2 (ru) 2004-11-10
HUP9802825A2 (hu) 1999-06-28
TR199901973T2 (xx) 1999-09-21
PL323087A1 (en) 1998-03-02
TR199701260T1 (xx) 1998-03-21
US6124337A (en) 2000-09-26
US5981563A (en) 1999-11-09
KR19990008131A (ko) 1999-01-25

Similar Documents

Publication Publication Date Title
MD1663C2 (ro) Compoziţie şi metode pentru modularea reacţiei sexuale umane şi tratamentul impotenţei
AU5876596A (en) Oral dosage and method for treating painful conditions of th e oral cavity
BG102744A (bg) Дозирана лекарствена форма на ибупрофен
IS4083A (is) Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja
ID24901A (id) Metode pengobatan keadaan terkoagulasi tinggi atau defisiensi protein c yang diperoleh
GEP20022783B (en) Method of Preventing and Delaying Onset of Alzheimer's Disease and Composition Therefor
EP0209689A3 (en) Use of tetrahydrobiopterins in the treatment of infantile autism
IL112518A0 (en) Thyroid hormone fast dispersing pharmaceutical composition
NO923859L (no) Medikament
MY164077A (en) Compositions and uses of et743 for treating cancer
UA90077C2 (uk) Антидисритмічні агенти для лікування тазового болю, що призначаються вагінально
ZA95679B (en) Products containing G-CSF and TNF binding protein
PL338673A1 (en) Application of fanquinone in treating alzheimer disease
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
IL118218A0 (en) Terpenoidic derivatives and pharmaceutical compositions containing them
HUT70521A (en) Process to prepare pharmaceutical comps. again amyloidosis
GR3034062T3 (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
MD518G2 (ro) Remediu pentru sporirea rezistenţei organismului uman
MD1469G2 (ro) Metodă de tratament al şocului combustional
MD1664F1 (ro) Metoda de profilaxie a recidivelor bolii ulceroase
PL325557A1 (en) Agent for use in prophylactics and/or treatmet of human and animal hair loss
MX9706188A (es) Inhibicion de la angiogenesis usando interleucina 12.
UA29025A (uk) Спосіб лікування ендокринної неплідності
GR1003066B (el) Καλλυντικα σκευασματα και φαρμακα που προερχονται απο τη χρηση των δραστικων συστατικων του φυτου hypericum perforatum
MX9605327A (es) Uso de ciertos derivados de acido metanbisfosfonico para prevenir el aflojamiento de las protesis y la emigracion de las protesis.

Legal Events

Date Code Title Description
PD99 Pending application